Bristol-Myers Claims Settlements Are Close In Lawsuits Over Generic Taxol, BuSpar
FDA Forms Office of Combination Products;
Obituary: Ellen Tobin, Consultant, Championed Patients’ Needs;
Report on Carcinogens Lists Estrogen, UV Light, Wood Dust;
Patent Policies Need Revision, Study of Hopkins, CellPro Dispute Concludes;
Funding Opportunities
Trending Stories
- An opportunity for Trump: Position U.S. cancer science to lead the world
- Former Maryland Governor Larry Hogan to receive Public Service Leadership Award from National Coalition for Cancer Survivorship
- The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear” - Grilled by Congress, Kennedy defends NIH and NCI budget cuts, freezes, and RIFs
To avoid “offending” pharma, NCI doesn’t study the causes of early-onset colon cancer, HHS secretary incorrectly alleges - NIH eliminates the NCI Board of Scientific Advisors
Over its 28 year history, BSA shaped NCI-funded extramural science - Kennedy’s claims notwithstanding, NCI clinical trials are delayed, enrollments reduced
NCI’s Steven A. Rosenberg: “Almost all patients are getting delayed by about a month, but then again, we’re turning away more patients.”